Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of Autologous Dendritic Cells Transduced With Adenoviruses Encoding the MART-1 and gp100 Melanoma Antigens Administered With or Without Low Dose Recombinant Interleukin-2 (rIL-2) in Patients With Stage IV Melanoma

Trial Profile

Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of Autologous Dendritic Cells Transduced With Adenoviruses Encoding the MART-1 and gp100 Melanoma Antigens Administered With or Without Low Dose Recombinant Interleukin-2 (rIL-2) in Patients With Stage IV Melanoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Aldesleukin; Melanoma vaccine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Aug 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified Jul 2002).
    • 23 Jul 2008 Planned patient number is 36 as reported bt ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top